From my basic research, Cognigram has been available in Canada since 2013, but I can't find much information from company reports regarding the level of market penetration or revenue that it has garnered... Do you believe that Cognigram will be a bigger commercial success in the United States? Don't get me wrong, I work in the cognitive sciences area, and can totally understand that Cognigram would be a fantastic product that provides a much-needed update to traditional pen/paper practises of screening for dementia/cognitive impairment. It would be great to hear how the company has learned from Canada in terms of whether they will tweak pricing/marketing tactics for the U.S. rollout. I guess more information in this regard will be provided across FY18.
Hoping to take up a (relatively) small-moderate position in CGS as more Cognigram info is provided.
Cheers
Ann: Cogstate selected as preferred provider for Lilly, page-10
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.010(0.89%) |
Mkt cap ! $187.8M | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.11 | $1.10 | $11.56K | 10.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 909 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 3500 | 1 |
View Market Depth
| Last trade - 14.36pm 01/07/2024 (20 minute delay) ? |
| CGS (ASX) Chart |